THE EFFICACY OF STATINS IN REDUCING CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ARTERY DISEASE: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/cq8eyk27Keywords:
Coronary artery disease, cardiovascular events, statin therapy.Abstract
Background: Statins significantly reduce cardiovascular events in individuals with coronary artery disease (CAD) by lowering LDL-C levels and modulating inflammatory pathways. Long-term adherence to statin therapy is crucial for sustained cardiovascular protection, preventing disease progression, and reducing the risk of adverse outcomes.
Methods: This systematic review adhered to PRISMA 2020 principles and focused exclusively on full-text papers published in English between 2015 and 2025. Editorials and review articles without a DOI were eliminated to preserve the integrity of high-quality sources. A literature review was conducted with esteemed databases like ScienceDirect, PubMed, and SagePub to discover relevant studies.
Result: The initial database search yielded over 1000 relevant publications on the topic. Following a comprehensive three-stage screening process, eight studies met the specified inclusion criteria and were selected for in-depth analysis. Each study was subjected to a thorough critical evaluation, enabling a comprehensive analysis of the efficacy of statins in reducing cardiovascular events in patients with coronary artery disease. This systematic method ensured that the analysis relied on high-quality evidence, aligned with the study's objectives, and was capable of providing significant insights into this complex association.
Conclusion: Statins show significant effects in reducing cardiovascular events in CAD patients, providing anti-inflammatory benefits, endothelial protection, and vascular function improvement. However, adherence remains a barrier, necessitating future research to enhance patient compliance and explore individualized statin therapy and lipid-lowering strategies for improved long-term outcomes.
References
Bansal AB, Cassagnol M. HMG-CoA Reductase Inhibitors. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542212/
Lee, Y. C., Hung, M. J., Chen, T. H., Mao, C. T., Yeh, C. T., Kounis, N. G., Chen, I. Y., Hu, P., & Hung, M. Y. (2024). Effects of statins in patients with coronary artery spasm: A nationwide population-based study. Clinical and translational science, 17(11), e70087. https://doi.org/10.1111/cts.70087
Soroush, N., Shahraki, M. N., Jouabadi, S. M., Amiri, M., Aribas, E., Stricker, B. H., & Ahmadizar, F. (2024). Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies. Nutrition Metabolism and Cardiovascular Diseases, 34(9), 2021–2033. https://doi.org/10.1016/j.numecd.2024.04.015
Diamantis, E., Kyriakos, G., Quiles-Sanchez, L. V., Farmaki, P., & Troupis, T. (2017). The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. Current cardiology reviews, 13(3), 209–216. https://doi.org/10.2174/1573403X13666170426104611
Oesterle, A., Laufs, U., & Liao, J. K. (2017). Pleiotropic effects of statins on the cardiovascular system. Circulation Research, 120(1), 229–243. https://doi.org/10.1161/circresaha.116.308537
Koushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021). Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways. Clinical reviews in allergy & immunology, 60(2), 175–199. https://doi.org/10.1007/s12016-020-08791-9
Jeong, H. Y., Lee, S. Y., Kim, S. H., & Kim, J. (2020). Long-Term Benefit and Withdrawal Effect of Statins After Percutaneous Coronary Intervention: A Nationwide Population-Based Cohort Study. Patient preference and adherence, 14, 717–724. https://doi.org/10.2147/PPA.S245324
Nowak, M. M., Niemczyk, M., Florczyk, M., Kurzyna, M., & Pączek, L. (2022). Effect of Statins on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis of Propensity Score-Matched Studies. Journal of clinical medicine, 11(19), 5643. https://doi.org/10.3390/jcm11195643
Lu, Y., Cheng, Z., Zhao, Y., Chang, X., Chan, C., Bai, Y., & Cheng, N. (2016). Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. Atherosclerosis, 254, 215–227. https://doi.org/10.1016/j.atherosclerosis.2016.10.025
Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., Clearfield, M., Colhoun, H., Collins, R., Dahlöf, B., Davies, K., Davis, B., De Lemos, J., Downs, J. R., Durrington, P., . . . Zannad, F. (2019). Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet, 393(10170), 407–415. https://doi.org/10.1016/s0140-6736(18)31942-1
Yebyo, H. G., Aschmann, H. E., Kaufmann, M., & Puhan, M. A. (2019). Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American Heart Journal, 210, 18–28. https://doi.org/10.1016/j.ahj.2018.12.007
Zhai, C., Hou, K., Li, R., Hu, Y., Zhang, J., Zhang, Y., Wang, L., Zhang, R., & Cong, H. (2020). Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis. The Journal of international medical research, 48(6), 300060520926349. https://doi.org/10.1177/0300060520926349
Fatima M, Wajid F (2023) Comparative Effectiveness of Statin Therapy in Reducing Cardiovascular Events. J Diabetes Metab Disord 10: 051.
Jaam, M., Al-Naimi, H. N., Haddad, M. M., Abushanab, D., & Al-Badriyeh, D. (2023). Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. Journal of comparative effectiveness research, 12(3), e220163. https://doi.org/10.57264/cer-2022-0163
Lee, Y., Hong, S., Kang, W. C., Hong, B., Lee, J., Lee, J., Cho, H., Yoon, J., Lee, S., Ahn, C., Kim, J., Kim, B., Ko, Y., Choi, D., Jang, Y., & Hong, M. (2023). Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ, e075837. https://doi.org/10.1136/bmj-2023-075837
Hafiz, A., Aljohani, S., Kutbi, H., Fatani, N., Alkhathran, L., Alyaqub, M., Alhamed, M. S., Alhaqbani, A. O., Alhadlaq, A. A., Alsalman, M. A., Yami, M. S. A., & Almohammed, O. A. (2025). Statin Use and Major Adverse Cardiovascular Events Among Patients with Ischemic Heart Diseases: A Multi-Center Retrospective Study. Journal of Clinical Medicine, 14(3), 908. https://doi.org/10.3390/jcm14030908
McPherson, R., Adreak, N., & Sharma, A. (2024). Medications for Lipid Control: Statins vs Newer Drugs. Canadian Journal of Cardiology, 40(8), S26–S34. https://doi.org/10.1016/j.cjca.2024.05.004
Cholesterol Treatment Trialists' Collaboration (2019). Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet (London, England), 393(10170), 407–415. https://doi.org/10.1016/S0140-6736(18)31942-1
Morofuji, Y., Nakagawa, S., Ujifuku, K., Fujimoto, T., Otsuka, K., Niwa, M., & Tsutsumi, K. (2022). Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer. Pharmaceuticals (Basel, Switzerland), 15(2), 151. https://doi.org/10.3390/ph15020151
Kim, K. H., Cho, S. H., Yim, Y. R., Lee, K. J., Yum, J. H., Yoon, H. J., Yoon, N. S., Hong, Y. J., Park, H. W., Kim, J. H., Ahn, Y., Jeong, M. H., Cho, J. G., & Park, J. C. (2013). Effects of Low Dose versus High Dose Statin Therapy on the Changes of Endothelial Function and Carotid Intima-Media Thickness in Patients with Variant Angina. Journal of Cardiovascular Ultrasound, 21(2), 58. https://doi.org/10.4250/jcu.2013.21.2.58
Alidadi, M., Montecucco, F., Jamialahmadi, T., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021). Beneficial effect of statin therapy on arterial stiffness. BioMed Research International, 2021, 1–19. https://doi.org/10.1155/2021/5548310
Laakso, M., & Fernandes Silva, L. (2023). Statins and risk of type 2 diabetes: mechanism and clinical implications. Frontiers in endocrinology, 14, 1239335. https://doi.org/10.3389/fendo.2023.1239335
Galicia-Garcia, U., Jebari, S., Larrea-Sebal, A., Uribe, K. B., Siddiqi, H., Ostolaza, H., Benito-Vicente, A., & Martín, C. (2020). Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. International journal of molecular sciences, 21(13), 4725. https://doi.org/10.3390/ijms21134725
Chen, Z., Wu, P., Wang, J., Chen, P., Fang, Z., & Luo, F. (2023). The association of statin therapy and cancer: a meta-analysis. Lipids in health and disease, 22(1), 192. https://doi.org/10.1186/s12944-023-01955-4
Lansberg, P., Lee, A., Lee, Z. V., Subramaniam, K., & Setia, S. (2018). Nonadherence to statins: individualized intervention strategies outside the pill box. Vascular health and risk management, 14, 91–102. https://doi.org/10.2147/VHRM.S158641
Giral, P., Neumann, A., Weill, A., & Coste, J. (2019). Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. European heart journal, 40(43), 3516–3525. https://doi.org/10.1093/eurheartj/ehz458
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
